Answers are grounded in this paper and cite their sources.
Case report details lenvatinib use leading to mycobacterial disease in a patient with hepatocellular carcinoma, suggesting therapy cessation benefits.
A 64‐year‐old man, with a history of hepatocellular carcinoma and long‐term oral lenvatinib treatment, was hospitalised in our institution twice due to ‘cough’. During hospitalisation, the patient underwent multiple bronchoscopies, with lavage fluid sent for pathogen testing, which returned negative results. Finally, Mycobacterium kansasii was detected via next‐generation sequencing (NGS). Considering the patient's poor hepatic reserve, we decided against initiating targeted antimicrobial therapy and discontinued lenvatinib. Two months after stopping lenvatinib, the patient's symptoms of cough and chest tightness improved. A follow‐up chest computed tomography (CT) on March 18, 2025, showed resolution of the lesions.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: